Intercell AG

euro adhoc: Intercell AG
quarterly or semiannual financial statement / Intercell announces Q3 results: Technologies continue to deliver new product candidates - Strong financial situation

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- 13.11.2006 Latest Achievements: » EU Grant of EUR 2.3 million for the development of an otitis media vaccine » EU Grant of EUR 3.5 million for the development of a pandemic influenza vaccine Technologies continue to create value and prime partnerships » Strategic alliance with Merck to develop a prophylactic vaccine against Group A Streptococcus - USD 85.5 million agreement » Strategic alliance with Wyeth for the use of Intercell’s IC31TM adjuvant in various selected infectious disease vaccines - payments up to USD 77 million » Collaboration with PATH for the development of Intercell’s Streptococcus pneumoniae vaccine - USD 7.3 m initial funding Significant progress in product development » Positive results for Intercell’s Japanese Encephalitis virus vaccine in the pivotal Phase III safety trial - Regulatory process towards a Biologics License Application (BLA) in the United States initiated » Intercell's therapeutic Hepatitis C T-cell vaccine advances to next Phase II clinical trial in chronic Hepatitis C patients using the optimized route and frequency of administration » Intercell terminates its preclinical collaborative development project for a therapeutic Hepatitis B vaccine in order to focus its partnership portfolio Financials: » Revenues were EUR 6.5 million for the first three quarters of 2006, compared to EUR 4.8 million in the same period of 2005 (up 35.4%) » Primarily due to advancement of JEV vaccine development, net loss increased by 21.8% to EUR 21.8 million in the nine months ended September 30, 2006 from EUR 17.9 million in the comparative period of 2005 » Strong cash position of EUR 83.7 million - strong cash-flows from strategic partnerships expected in Q4 2006 Vaccine company Intercell AG (VSE: ICLL) today announced its financial results for the third quarter of 2006. Intercell’s aggregate revenues in the nine months ended September 30, 2006 were EUR 6.5 million, compared to EUR 4.8 million in the same period of 2005. This 35.4 percent increase was due to higher revenues from collaborations and licensing, which increased by 55.6 percent from EUR 3.6 million in the first nine months of 2005 to EUR 5.6 million in the first nine months of 2006. Grant income decreased by 25.0 percent, from EUR 1.2 million in the first three quarters of 2005 to EUR 0.9 million in the first three quarters of 2006. Intercell’s net loss increased by EUR 3.9 million, or by 21.8 percent, from EUR 17.9 million in the first nine months of 2005 to EUR 21.8 million in the nine months ended September 30, 2006. This increase in net loss was due to an increase in research and development expenses of 24.6 percent and an increase in sales, general and administrative expenses of 18.3 percent. Research and development expenses were EUR 21.8 million in the first three quarters of 2006, compared to EUR 17.5 million in the first three quarters of 2005. This increase was primarily due to increased costs relating to the Phase III clinical trials for Intercell’s JEV vaccine. Sales general and administrative expenses increased to EUR 7.1 million in the nine months ended September 30, 2006 from EUR 6.0 million in the same period of 2005 and resulted primarily from higher personnel expenses. In aggregate, net operating expenses in the first three quarters of 2006 increased by 18.8 percent to EUR 27.8 million, from EUR 23.4 million in the first nine months of 2005. Financial Highlights EUR in thousands 9 months ended Year ended Sept. 30, 2006 Sept. 30, 2005 Dec. 31, 2005 Revenues 6,483 4,797 8,469 Net loss (21,761) (17,890) (25,060) Net operating cash flow (18,059) (16,166) (24,023) Cash and marketable securities, end of period 83,711 59,701 50,178 The full quarterly report including un-audited financial statements can be downloaded at www.intercell.com. end of announcement euro adhoc 13.11.2006 07:00:31 -------------------------------------------------------------------------------- ots Originaltext: Intercell AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Intercell AG Mag. Katharina Wieser Head of Corporate Communications Tel. +43 1 20620-303 kwieser@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Börsen: Wiener Börse AG / official market

Das könnte Sie auch interessieren: